APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatophytosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dermatophytosis Drugs Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchDermatophytosis Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatophytosis Drugs Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Dermatophytosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatophytosis Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatophytosis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Dermatophytosis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dermatophytosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dermatophytosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatophytosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dermatophytosis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dermatophytosis Drugs market include Astellas Pharma, Enzon Pharmaceuticals, Sanofi-Aventis, Bayer, GSK, Pfizer, Merck, Novartis and Abbott, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Dermatophytosis Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dermatophytosis Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dermatophytosis Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Dermatophytosis Drugs market.

Dermatophytosis Drugs Segment by Company

Astellas Pharma

Enzon Pharmaceuticals

Sanofi-Aventis

Bayer

GSK

Pfizer

Merck

Novartis

Abbott

Dermatophytosis Drugs Segment by Type

Rx

OTC

Dermatophytosis Drugs Segment by Application

Hospital

Clinic

Other

Dermatophytosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dermatophytosis Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Dermatophytosis Drugs key companies, revenue, market share, and recent developments.

3. To split the Dermatophytosis Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Dermatophytosis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dermatophytosis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Dermatophytosis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatophytosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatophytosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatophytosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dermatophytosis Drugs industry.

Chapter 3: Detailed analysis of Dermatophytosis Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Dermatophytosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Dermatophytosis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dermatophytosis Drugs Industry Trends Table 2. Dermatophytosis Drugs Industry Drivers Table 3. Dermatophytosis Drugs Industry Opportunities and Challenges Table 4. Dermatophytosis Drugs Industry Restraints Table 5. Global Dermatophytosis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dermatophytosis Drugs Revenue Share by Company (2021-2026) Table 7. Global Dermatophytosis Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Dermatophytosis Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Dermatophytosis Drugs Company, Product Type & Application Table 10. Global Dermatophytosis Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Dermatophytosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Rx Table 15. Significant Companies of OTC Table 16. Global Dermatophytosis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Dermatophytosis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Dermatophytosis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Dermatophytosis Drugs Sales Value Share by Type (2021-2026) Table 20. Global Dermatophytosis Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Dermatophytosis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Dermatophytosis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Dermatophytosis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Dermatophytosis Drugs Sales Value Share by Application (2021-2026) Table 28. Global Dermatophytosis Drugs Sales Value Share by Application (2027-2032) Table 29. Global Dermatophytosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Dermatophytosis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Dermatophytosis Drugs Sales Value Share by Region (2021-2026) Table 32. Global Dermatophytosis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Dermatophytosis Drugs Sales Value Share by Region (2027-2032) Table 34. Global Dermatophytosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Dermatophytosis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Dermatophytosis Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Dermatophytosis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Dermatophytosis Drugs Sales Value Market Share by Country (2027-2032) Table 39. Astellas Pharma Company Information Table 40. Astellas Pharma Business Overview Table 41. Astellas Pharma Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Astellas Pharma Dermatophytosis Drugs Product Portfolio Table 43. Astellas Pharma Recent Development Table 44. Enzon Pharmaceuticals Company Information Table 45. Enzon Pharmaceuticals Business Overview Table 46. Enzon Pharmaceuticals Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Enzon Pharmaceuticals Dermatophytosis Drugs Product Portfolio Table 48. Enzon Pharmaceuticals Recent Development Table 49. Sanofi-Aventis Company Information Table 50. Sanofi-Aventis Business Overview Table 51. Sanofi-Aventis Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi-Aventis Dermatophytosis Drugs Product Portfolio Table 53. Sanofi-Aventis Recent Development Table 54. Bayer Company Information Table 55. Bayer Business Overview Table 56. Bayer Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bayer Dermatophytosis Drugs Product Portfolio Table 58. Bayer Recent Development Table 59. GSK Company Information Table 60. GSK Business Overview Table 61. GSK Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. GSK Dermatophytosis Drugs Product Portfolio Table 63. GSK Recent Development Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pfizer Dermatophytosis Drugs Product Portfolio Table 68. Pfizer Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck Dermatophytosis Drugs Product Portfolio Table 73. Merck Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis Dermatophytosis Drugs Product Portfolio Table 78. Novartis Recent Development Table 79. Abbott Company Information Table 80. Abbott Business Overview Table 81. Abbott Dermatophytosis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Abbott Dermatophytosis Drugs Product Portfolio Table 83. Abbott Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Dermatophytosis Drugs Product Image Figure 2. Global Dermatophytosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatophytosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Dermatophytosis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Rx Image Figure 8. OTC Image Figure 9. Global Dermatophytosis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Dermatophytosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Dermatophytosis Drugs Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Dermatophytosis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Dermatophytosis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Dermatophytosis Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Dermatophytosis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Dermatophytosis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Dermatophytosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Dermatophytosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Dermatophytosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Dermatophytosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Dermatophytosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Dermatophytosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Dermatophytosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Dermatophytosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Dermatophytosis Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Dermatophytosis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Dermatophytosis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Rx
  • OTC
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Astellas Pharma
  • Enzon Pharmaceuticals
  • Sanofi-Aventis
  • Bayer
  • GSK
  • Pfizer
  • Merck
  • Novartis
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dermatophytosis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dermatophytosis Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Dermatophytosis Drugs Market Dynamics
  1. 2.1 Dermatophytosis Drugs Industry Trends
  2. 2.2 Dermatophytosis Drugs Industry Drivers
  3. 2.3 Dermatophytosis Drugs Industry Opportunities and Challenges
  4. 2.4 Dermatophytosis Drugs Industry Restraints
3 Dermatophytosis Drugs Market by Company
  1. 3.1 Global Dermatophytosis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Dermatophytosis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Dermatophytosis Drugs Company Ranking (2024-2026)
  4. 3.4 Global Dermatophytosis Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Dermatophytosis Drugs Company Product Type and Application
  6. 3.6 Global Dermatophytosis Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Dermatophytosis Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Dermatophytosis Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Dermatophytosis Drugs Market by Type
  1. 4.1 Dermatophytosis Drugs Type Introduction
  2. 4.1.1 Rx
  3. 4.1.2 OTC
  4. 4.2 Global Dermatophytosis Drugs Sales Value by Type
  5. 4.2.1 Global Dermatophytosis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Dermatophytosis Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Dermatophytosis Drugs Sales Value Share by Type (2021-2032)
5 Dermatophytosis Drugs Market by Application
  1. 5.1 Dermatophytosis Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Dermatophytosis Drugs Sales Value by Application
  6. 5.2.1 Global Dermatophytosis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dermatophytosis Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Dermatophytosis Drugs Sales Value Share by Application (2021-2032)
6 Dermatophytosis Drugs Regional Value Analysis
  1. 6.1 Global Dermatophytosis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dermatophytosis Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Dermatophytosis Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Dermatophytosis Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dermatophytosis Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Dermatophytosis Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Dermatophytosis Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Dermatophytosis Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Dermatophytosis Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Dermatophytosis Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Dermatophytosis Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Dermatophytosis Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Dermatophytosis Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Dermatophytosis Drugs Sales Value Share by Country, 2025 VS 2032
7 Dermatophytosis Drugs Country-level Value Analysis
  1. 7.1 Global Dermatophytosis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dermatophytosis Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Dermatophytosis Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Dermatophytosis Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Dermatophytosis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Dermatophytosis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Dermatophytosis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma
  2. 8.1.1 Astellas Pharma Company Information
  3. 8.1.2 Astellas Pharma Business Overview
  4. 8.1.3 Astellas Pharma Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma Dermatophytosis Drugs Product Portfolio
  6. 8.1.5 Astellas Pharma Recent Developments
  7. 8.2 Enzon Pharmaceuticals
  8. 8.2.1 Enzon Pharmaceuticals Company Information
  9. 8.2.2 Enzon Pharmaceuticals Business Overview
  10. 8.2.3 Enzon Pharmaceuticals Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Enzon Pharmaceuticals Dermatophytosis Drugs Product Portfolio
  12. 8.2.5 Enzon Pharmaceuticals Recent Developments
  13. 8.3 Sanofi-Aventis
  14. 8.3.1 Sanofi-Aventis Company Information
  15. 8.3.2 Sanofi-Aventis Business Overview
  16. 8.3.3 Sanofi-Aventis Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi-Aventis Dermatophytosis Drugs Product Portfolio
  18. 8.3.5 Sanofi-Aventis Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Dermatophytosis Drugs Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GSK Dermatophytosis Drugs Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Dermatophytosis Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Dermatophytosis Drugs Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Dermatophytosis Drugs Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Abbott
  50. 8.9.1 Abbott Company Information
  51. 8.9.2 Abbott Business Overview
  52. 8.9.3 Abbott Dermatophytosis Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Abbott Dermatophytosis Drugs Product Portfolio
  54. 8.9.5 Abbott Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst